T cell vaccination in secondary progressive multiple sclerosis

Area of Science:

• Immunology
• Neuroscience
• Cell Biology

Background:

• Multiple sclerosis (MS) involves immune system attacks on myelin.
• Current MS treatments often focus on broad immunosuppression.
• Targeting specific autoreactive T cells offers a potential therapeutic strategy.

Purpose of the Study:

• To evaluate the safety and immunologic effects of T cell vaccination (TCV) in secondary progressive MS patients.
• To assess the impact of TCV on myelin-reactive T cells and clinical outcomes.

Main Methods:

• Four secondary progressive MS patients received autologous, irradiated bovine myelin-reactive T cell lines.
• Patients were monitored for immunological responses and clinical status (EDSS) over 30-39 months.
• Circulating T cells specific for myelin antigens and tetanus toxoid were quantified.
• T cell lines (TCL) were isolated and characterized for their reactivity and cytotoxic activity.

Main Results:

• Two patients maintained stable EDSS scores, one improved, and one worsened.
• TCV led to a decline in myelin-specific T cells (including MBP, PLP, MOG peptides) and myelin-specific IL-2/IFN-gamma production.
• Tetanus toxoid-reactive T cells remained unchanged, indicating antigen specificity.
• Isolated TCL demonstrated MHC Class I and II restricted lysis of myelin-reactive T cells.
• IL-10 produced by some TCL inhibited myelin-specific T cell proliferation.

Conclusions:

• TCV with autologous irradiated myelin-reactive T cells effectively depletes T cells reactive against various myelin antigens.
• This approach demonstrates antigen-specific immune modulation in MS.
• TCV shows promise as a targeted therapy for multiple sclerosis by reducing autoreactivity.